Florida is currently home to 3826 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Autoimmune Encephalitis, Encephalitis
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
Recruiting
The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology findings), to optimise patient outcomes. To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival in the reduced intensity treatment a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Advent Health, Orlando, Florida
Conditions: Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
Recruiting
The purpose of this study is to evaluate the efficacy and safety of an adjuvant treatment of therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in patients with HER2-low expression (IHC 1+ or 2+ and ISH-) and hormone receptor-negative(ER-, PR-) breast cancer with residual disease after neoadjuvant treatment. Patients will be randomized 1:1 to either the Experimental arm (combination of AST-301/rhuGM CSF and standard adjuvant therapy) or the Control arm (combination of placebo/rhuGM CSF and stand... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer
VIA Disc NP Registry
Recruiting
Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: The Orthopedic Institute, Gainesville, Florida
Conditions: Discogenic Pain, Back Pain, Back Pain, Low
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
Recruiting
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
07/18/2023
Locations: Qps-Mra, Llc., South Miami, Florida
Conditions: Healthy
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
Recruiting
This registry will evaluate treatment selection for patients with newly diagnosed, localized prostate cancer following Prolaris testing. It will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: Manatee Medical Research Institute, Bradenton, Florida
Conditions: Prostate Cancer
Developing Strategies for Effective Debridement in Patients for Venous Leg Ulcers
Recruiting
The goal of this project is to use genomic profiling, candidate genes and proteins to develop guided surgical debridement to improve healing in chronic non-healing venous leg ulcers (VLUs) and to test the efficacy of this approach.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: University of Miami, Miami, Florida
Conditions: Venous Leg Ulcer
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Recruiting
Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
07/18/2023
Locations: Memorial Healthcare System, Hollywood, Florida
Conditions: Chronic Kidney Disease; Iron Deficiency Anemia
Study to Assess PDM608 in Healthy Adult Subjects
Recruiting
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
07/17/2023
Locations: Quotient Sciences-Miami, Inc, Miami, Florida
Conditions: Parkinson Disease
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
Recruiting
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/17/2023
Locations: Clermont Oncology Center, Clermont, Florida
Conditions: Carcinoma, Non-Small-Cell Lung
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Recruiting
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/17/2023
Locations: Scri Florida Cancer Specialists South, Fort Myers, Florida
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
All
Ages:
All
Trial Updated:
07/17/2023
Locations: RANGER: University of Miami, Miami, Florida
Conditions: Peripheral Nerve Injuries